Zelira Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZLD.AX research report →
Price Chart
About the company
Zelira Therapeutics Limited (ZLD. AX) is an Australian biopharmaceutical firm dedicated to the research, development, and commercialization of cannabinoid-derived medicines for a variety of medical conditions. Its product portfolio includes HOPE™ brand formulations, which are available in Pennsylvania and Louisiana, as well as Zenivol™, a cannabinoid-based medication designed to treat chronic insomnia.
- CEO
- Oludare Odumosu
- IPO
- 2003
- Employees
- 8
- HQ
- Perth, WA, AU
Get TickerSpark's AI analysis on ZLD.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.57M
- P/E
- -1.56
- PEG
- -0.01
- P/S
- 10020.70
- P/B
- -1.29
- EV/EBITDA
- -2.09
- Div Yield
- 0.00%
- Gross Margin
- -122400.15%
- Op Margin
- -602467.84%
- Net Margin
- -553029.27%
- ROE
- 80.84%
- ROIC
- 128.84%
Latest fiscal year · YoY change
- Revenue
- $656-99.3%
- Gross Profit
- $-802,945-7907.7%
- Op Income
- $-3,952,189
- Net Income
- $-3,627,872+90.1%
- EPS
- $-0.32+90.1%
- OCF Growth
- -11.8%
- FCF Growth
- -11.8%
- 52W High
- $1.15
- 52W Low
- $0.31
- 50D MA
- $0.57
- 200D MA
- $0.43
- Beta
- 0.59
- RSI (14)
- 38
- Avg Volume
- 45.05K
No earnings-call transcripts are available for ZLD.AX yet.
- Free Float
- 95.5%
- Shares Outstanding
- 13.15M
- Float Shares
- 12.56M
Our ZLD.AX coverage
Recent articles, reports, and earnings notes.
No research on ZLD.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZLD.AX report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.